Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
ORIC
Stock Latest News
The Fly
Oric Pharmaceuticals price target raised to $22 from $21 at H.C. Wainwright
3d ago
ORIC
Premium
Ratings
ORIC Pharmaceuticals: A Promising Buy with Upcoming Data Catalysts and Competitive Safety Profile
5d ago
ORIC
Premium
Company Announcements
ORIC Pharmaceuticals Reports Q1 2025 Progress and Plans
6d ago
ORIC
Premium
The Fly
Oncology stocks ‘bearing the brunt’ of Prasad news, says Oppenheimer
6d ago
IDYA
NRIX
Premium
The Fly
Oric Pharmaceuticals price target lowered to $12 from $15 at Oppenheimer
6d ago
ORIC
Premium
Ratings
Buy Rating for Oric Pharmaceuticals: Promising Pipeline and Strong Financial Position
6d ago
ORIC
Premium
The Fly
Oric Pharmaceuticals reports Q1 EPS (42c), consensus (50c)
7d ago
ORIC
Premium
The Fly
Oric Pharmaceuticals presents preclinical ORIC-944 data at AACR
14d ago
ORIC
Premium
Company Announcements
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth
2M ago
8K
ORIC
Premium
Company Announcements
ORIC Pharmaceuticals Reports Progress in Cancer Trials
2M ago
ORIC
Premium
Ratings
Positive Outlook for Oric Pharmaceuticals: Buy Rating Affirmed on Promising ORIC-944 Updates and Strategic Refocus
3M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114
3M ago
ORIC
Premium
Ratings
Positive Growth Outlook for Oric Pharmaceuticals Driven by Clinical Catalysts and Financial Stability
3M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals reports Q4 EPS (51c), consensus (51c)
3M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals announces upcoming milestones
3M ago
ORIC
Premium
Ratings
Buy Rating on Oric Pharmaceuticals: Capitalizing on Prostate Cancer Treatment Advances
3M ago
ORIC
Premium
The Fly
Oric recent weakness a buying opportunity, says JPMorgan
3M ago
PFE
ORIC
Premium
Ratings
Promising Efficacy and Manageable Safety of ORIC-944 Positions ORIC Shares Favorably
3M ago
ORIC
Premium
Ratings
Positive Outlook for Oric Pharmaceuticals Driven by Promising Trial Results of Mevrometostat and Xtandi Combination
3M ago
ORIC
Premium
Ratings
Oric Pharmaceuticals: Promising Trials and Strong Financials Justify Buy Rating
3M ago
ORIC
Premium
The Fly
Cantor says Oric accidental release looks ‘very positive’ for mevrometostat
3M ago
ORIC
Premium
Ratings
Optimistic Buy Rating for Oric Pharmaceuticals Driven by Promising Data and Favorable Risk/Reward Profile
3M ago
ORIC
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.